Avascular necrosis in sickle cell disease can occur due to the impairment of blood supply to the bones, writes columnist.

Many high risk, high reward medical therapies that use cutting edge science are proving themselves in clinical trials. But are health services ready to pay for them—and how? Marianne Guenot reports On ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with sickle cell disease (SCD), according to new research published in Blood ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy ... based therapy will be an option for SCD patients aged 12 years and over who have ...

In a new study, researchers found that the inflammation behind painful episodes in sickle cell disease are correlated with ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

Patients with genetic disorders such as thalassemia and sickle cell disease will greatly benefit from this revolutionary ... Hisham Hagar, Senior Country Manager at Vertex GCC, said: “We are delighted ...

Patients with genetic disorders such as thalassemia and sickle cell disease will greatly benefit ... Hisham Hagar, Senior Country Manager at Vertex GCC, said: “We are delighted to partner ...

Vertex’s effort to provide fertility ... offering up to $70,000 for fertility procedures for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT ...